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Platelet Inhibition and Bleeding Complications in Cardiac Surgery Patients 
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EMMA C. HANSSON 
Department of Molecular and Clinical Medicine, Institute of Medicine,  
Sahlgrenska Academy, University of Gothenburg, Sweden 
BACKGROUND AND OBJECTIVE: Dual antiplatelet therapy (DAPT) with acetylsalicylic acid 
and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces thrombotic events in patients with 
acute coronary syndrome (ACS), but it is also associated with an increased risk of bleeding 
complications. The aim of this project was to investigate the prevalence and effects of platelet 
inhibition in the context of cardiac surgery, the bleeding problems that may occur, and treatment of 
bleeding complications. 
METHODS: Studies I and II investigated the incidence of CABG-related bleeding complications 
with DAPT in relation to time from discontinuation. Study I was a regional pilot study and Study II 
was a nationwide registry analysis. Studies III and IV were experimental ex vivo studies of platelet 
function in patients treated with platelet inhibitors, as measured by multiple-electrode aggregometry. 
Study III investigated the effects of platelet transfusion in patients with different platelet inhibitors, 
and Study IV examined the effects at time points after discontinuation. Study IV also investigated the 
recovery of platelet aggregability after discontinuation of ticagrelor. Study V examined the role of 
platelet inhibition in patients operated for acute aortic dissection. 
RESULTS: The incidence of CABG-related major bleeding was high when DAPT was discontinued 
< 24 hours before surgery. Discontinuation 3 days before surgery, as opposed to 5 days, did not 
increase the incidence with ticagrelor, but increased the risk with clopidogrel. The overall risk of 
major bleeding was lower with ticagrelor than with clopidogrel. Platelet supplementation improved 
platelet aggregability independently of antiplatelet therapy. However, the effect on ADP-induced 
platelet aggregation was limited, and it was reduced further with ticagrelor compared to clopidogrel. 
Platelet concentrate did not improve aggregation at later time points after discontinuation of 
ticagrelor. Platelet aggregation recovered to levels not associated with bleeding 72 hours after 
ticagrelor, but with large inter-individual variation. The indication for antiplatelet therapy in patients 
operated for acute aortic dissection was weak or absent in most cases. Patients with ongoing platelet 
inhibition at the time of aortic repair had more bleeding complications, and DAPT was associated 
with increased early mortality. 
CONCLUSIONS: DAPT with ticagrelor allows shorter discontinuation time before surgery than 
clopidogrel, and timing of surgery may be aided by platelet function testing. In case of bleeding, 
platelet transfusion can be expected to improve platelet function, but less so in ticagrelor-treated 
patients than in clopidogrel-treated patients. It is important to carefully consider the indication for 
DAPT before treatment is started in patients who may undergo surgery. 
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